Literature DB >> 2258607

Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients.

A Jewett1, J V Giorgi, B Bonavida.   

Abstract

Cytotoxic effector cells like cytotoxic T cells, NK cells, monocytes/macrophages, and neutrophils can lyse directly HIV-infected or HIV-coated cells in the absence or presence of anti-HIV antibodies. Therefore, these cytotoxic mechanisms can be invoked either in the control of HIV infection at early stages of the disease or in the generalized immunosuppression observed at later stages of the disease. The relationship between anti-HIV effector mechanisms and disease, however, remains elusive. The present study investigates in HIV+ seropositive asymptomatic patients peripheral blood monocytes (PBM)-mediated antibody dependent cellular cytotoxicity (ADCC) against HIV-coated target cells in the presence of heterologous or autologous anti-HIV serum. To test for specific ADCC against HIV Ag, a T4+ CEM.TR line resistant to TNF and macrophage-mediated cytotoxicity was selected in vitro. ADCC was performed in an 18-h 51Cr-release assay using CEM.TR cells coated with inactivated HIV. Unlike PBM from normal controls, significant ADCC was observed by PBM from HIV+ seropositive patients in the presence of pooled HIV+ antiserum. The ADCC activity was specific for HIV and was dependent on the E:T ratio and the antiserum dilution used. Upon activation of PBM with rIFN-gamma, both normal and HIV+ PBM-mediated ADCC against HIV-coated CEM.TR. Furthermore, ADCC activity by PBM from HIV+ seropositive patients in the presence of their autologous serum was examined. Significant ADCC activity was observed and was dependent on the E:T ratio and serum dilution used. The findings demonstrating anti-HIV ADCC activity by PBM from HIV+ seropositive individuals and their autologous sera support the notion that monocyte-mediated ADCC may be operative in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258607

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Authors:  Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.

Authors:  D N Forthal; G Landucci; E S Daar
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads.

Authors:  Pratip Nag; Jenney Kim; Vytautas Sapiega; Alan L Landay; James W Bremer; Jiri Mestecky; Patricia Reichelderfer; Andrea Kovacs; Jonathan Cohn; Barbara Weiser; Linda L Baum
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

4.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

5.  Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

Authors:  Yida Yang; Ilia Tikhonov; Tracy J Ruckwardt; Mahmoud Djavani; Juan Carlos Zapata; C David Pauza; Maria S Salvato
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

7.  Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.

Authors:  Vincent Holl; Maryse Peressin; Christiane Moog
Journal:  Viruses       Date:  2009-12-15       Impact factor: 5.048

8.  Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice.

Authors:  K M Hege; K S Cooke; M H Finer; K M Zsebo; M R Roberts
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

9.  Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

Authors:  T S Griffith; S R Wiley; M Z Kubin; L M Sedger; C R Maliszewski; N A Fanger
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.